<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02262702</url>
  </required_header>
  <id_info>
    <org_study_id>202175</org_study_id>
    <secondary_id>RH01690</secondary_id>
    <nct_id>NCT02262702</nct_id>
  </id_info>
  <brief_title>Panadol Osteo Pharmaceuticals Benefit Scheme (PBS) Claims Cohort Study</brief_title>
  <official_title>Panadol Osteo PBS Claims Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this observational study is to compare the use of an extended release paracetamol
      formulation with standard paracetamol in a cohort of Australian concessional patients with
      osteoarthritis (OA), to assess differences in prescribing patterns and patient compliance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This retrospective analysis of physician prescribing data (long-term concessional cohort from
      the Medicare Australia PBS claims dataset for the time period 2008-2011 (4 years) will
      compare the use of extended release paracetamol (Panadol Osteo) with standard paracetamol
      500mg in a cohort of Australian concessional patients with OA, to assess differences in
      prescribing patterns and patient compliance.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relative number of prescriptions of an extended release paracetamol formulation and a standard release paracetamol formulation.</measure>
    <time_frame>January 2009 to December 2010</time_frame>
    <description>Number of episodes of treatment for OA with the extended release formulation and the standard release formulatins will be counted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative treatment compliance with an extended release paracetamol formulation and a standard release paracetamol formulation</measure>
    <time_frame>January 2009 to December 2010</time_frame>
    <description>Interval between the repeat doses of extended release paracetamol formulation and the standard release paracetamol formulation.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Extended Release Paracetamol</arm_group_label>
    <description>Participants prescribed with extended release paracetamol tablet containing 665 mg paracetamol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Paracetamol</arm_group_label>
    <description>Participants prescribed with standard paracetamol tablet containing 500 mg paracetamol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol 665 mg</intervention_name>
    <description>Paracetamol 665 mg tablet</description>
    <arm_group_label>Extended Release Paracetamol</arm_group_label>
    <other_name>Panadol Osteo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol 500 mg</intervention_name>
    <description>Paracetamol 500 mg tablet</description>
    <arm_group_label>Standard Paracetamol</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort of Australian concessional patients with osteoarthritis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants prescribed with a paracetamol product and categorized as a concessional
             patient

          -  Participants with new episodes of OA (no history of OA paracetamol in previous 12
             months) or suffering from chronic OA (history of OA paracetamol in the previous 12
             months)

        Exclusion Criteria:

          -  Participants with Rheumatoid arthritis or other auto-immune inflammatory conditions

          -  Participants receiving the following anti-rheumatoid therapies:Immunimodulators such
             as methotrexate, leflunamide and TNF blockers

          -  Participants receiving treatment for cancer pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2014</study_first_posted>
  <last_update_submitted>January 21, 2016</last_update_submitted>
  <last_update_submitted_qc>January 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

